Genome-editing tool could increase cancer risk

June 11, 2018, Karolinska Institutet
Bernhard Schmierer, research team leader at the Department of Medical Biochemistry and Biophysics, Karolinska Institutet. Credit: Ulf Sirborn

Therapeutic use of gene editing with the CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study from Karolinska Institutet, Sweden, and the University of Helsinki, Finland, published in Nature Medicine. Researchers say that more studies are required in order to guarantee the safety of these 'molecular scissors' for gene-editing therapies.

CRISPR-Cas9 is a molecular machine first discovered in bacteria that can be programmed to go to an exact place in the genome, where it cuts the DNA. These precise 'molecular scissors' can be used to correct faulty pieces of DNA and are currently being used in clinical trials for cancer immunotherapy in the U.S. and China. New trials are expected to be launched soon to treat inherited blood disorders such as sickle cell anaemia.

Two independent articles published in the journal Nature Medicine now report that therapeutic application of the genome-editing tool may, in fact, increase the risk of cancer. In one of the studies, scientists from Karolinska Institutet and the University of Helsinki report that use of CRISPR-Cas9 in human cells in a laboratory setting can activate a protein known as p53, which acts as a cell's 'first aid kit' for DNA breaks. Once active, p53 reduces the efficiency of CRISPR-Cas9 gene editing. Thus, cells that do not have p53 or are unable to activate it show better gene editing. Unfortunately, however, lack of p53 is also known to contribute to making cells grow uncontrollably and become cancerous.

"By picking cells that have successfully repaired the damaged gene we intended to fix, we might inadvertently also pick cells without functional p53," says Dr. Emma Haapaniemi, researcher at the Department of Medicine at Karolinska Institutet in Huddinge and co-first author of the study. "If transplanted into a patient, as in gene therapy for inherited diseases, such cells could give rise to cancer, raising concerns for the safety of CRISPR-based gene therapies."

"CRISPR-Cas9 is a powerful tool with staggering therapeutic potential," adds Dr. Bernhard Schmierer, researcher at the Department of Medical Biochemistry and Biophysics at Karolinska Institute, who co-supervised the study. "Like all medical treatments however, CRISPR-Cas9-based therapies might have side effects, which the patients and caregivers should be aware of. Our study suggests that future work on the mechanisms that trigger p53 in response to CRISPR-Cas9 will be critical in improving the safety of CRISPR-Cas9-based therapies."

Explore further: Alternative CRISPR system is less specific, more robust

More information: Emma Haapaniemi et al, CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response, Nature Medicine (2018). DOI: 10.1038/s41591-018-0049-z

Related Stories

Alternative CRISPR system is less specific, more robust

September 13, 2017
The genetic tool adept at line-by-line gene editing, CRISPR, has revolutionized the ability of scientists to manipulate genes for experimental, and perhaps someday therapeutic, purposes. But it comes in several varieties. ...

Genome editing method targets AIDS virus

May 18, 2018
By destroying the regulatory genes of the AIDS virus HIV-1 using the genome editing system CRISPR/Cas9, a Japanese research group has succeeded in blocking the production of HIV-1 by infected cells.

Modifying fat content in soybean oil with the molecular scissors Cpf1

February 16, 2017
A team from the Center for Genome Engineering, within the Institute for Basic Research (IBS), succeeded in editing two genes that contribute to the fat contents of soybean oil using the new CRISPR-Cpf1 technology: an alternative ...

CAR T cells more powerful when built with CRISPR, researchers find

February 22, 2017
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, ...

New genome-editing method 'cuts back' on unwanted genetic mutations

February 5, 2018
Gene therapy is an emerging strategy to treat diseases caused by genetic abnormalities. One form of gene therapy involves the direct repair of a defective gene, using genome-editing technology such as CRISPR-Cas9. Despite ...

Salk scientists adapt powerful gene-editing system to correct dementia in lab

March 20, 2018
The revolutionary CRISPR/Cas9 gene editing system made it possible to rapidly and precisely alter DNA, the essential molecule of life. But DNA doesn't work by itself, it relies on the messenger molecule RNA to carry out its ...

Recommended for you

New algorithm could improve diagnosis of rare diseases

August 17, 2018
Today, diagnosing rare genetic diseases requires a slow process of educated guesswork. Gill Bejerano, Ph.D., associate professor of developmental biology and of computer science at Stanford, is working to speed it up.

Gene silencing critical for normal breast development

August 17, 2018
Researchers have discovered that normal breast development relies on a genetic 'brake', a protein complex that keeps swathes of genes silenced.

Officials remove special rules for gene therapy experiments

August 16, 2018
U.S. health officials are eliminating special regulations for gene therapy experiments, saying that what was once exotic science is quickly becoming an established form of medical care with no extraordinary risks.

Genetic link discovered between circadian rhythms and mood disorders

August 15, 2018
Circadian rhythms are regular 24-hour variations in behaviour and activity that control many aspects of our lives, from hormone levels to sleeping and eating habits.

Ovarian cancer genetics unravelled

August 14, 2018
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease, and could be used to personalise treatment in future.

New genome-editing strategy could lead to therapeutics

August 14, 2018
Researchers at UMass Medical School have developed a genome-editing strategy to correct disease-causing DNA mutations in mouse models of human genetic diseases, according to research published in the Aug. 18 edition of Nature ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.